~~<i id='B15D939B84'><strike id='B15D939B84'><tt id='B15D939B84'><pre id='B15D939B84'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：focus 2025-09-30 15:16:32 - browse：56

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Melinda French Gates resigns from Gates Foundation

explore

hotspot

focus

hotspot

entertainment

focus

In2020,JamesSulzer’spersonalandprofessionallivessuddenlyintersectedafterhisthen4-year-olddaughtersus

WSS

Dogs on Prozac: What pet anti

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Orangutan used medicinal plant to treat wound, first time ever seen

MassMutual is introducing free genetic testing for members

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Dogs on Prozac: What pet anti

focus

hotspot

explore

Continuity nursing helped my family in our darkest PICU moments

Key Senate committee drafts bipartisan bill to stem drug shortages

Apple is now the first public company to be valued at $3 trillion

Melinda French Gates resigns from Gates Foundation

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FogPharma raises $145 million in rare Series E round

United colonoscopy coverage change 'may cost lives,' doctors say

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Trump demands the U.S. pay no more for drugs than other countries … again

More tobacco lobbyists active in statehouses

hotspot

Element Biosciences CEO lays out genome sequencing strategy

Cue Health's Covid

MultiPlan and major insurers sued for alleged medical price

RSV vaccines may be linked to small increased risk of developing GBS

Scientists unlock the key to scar

H5N1 bird flu virus started spreading in cows in Texas in December

focus

hotspot

entertainment

focus